- In February 2024, Bayer AG partnered with DARÉ BIOSCIENCE to enhance the development of an innovative hormone-free monthly contraceptive option. This collaboration aims to address the growing demand for non-hormonal contraceptive methods, providing consumers with more choices in family planning. By combining their expertise, the two companies seek to advance reproductive health solutions and improve accessibility to effective contraceptive alternatives
- In February 2023, the Family Planning Association of India (FPAI) launched efforts to promote Implanon NXT, a new contraceptive option. This subdermal single-rod implant offers a long-term, reversible contraceptive solution, providing a modern alternative to older implant types such as Norplant, Jadelle, Sino-implant, and the original Implanon. By advocating for Implanon NXT, FPAI aims to enhance reproductive health choices and improve accessibility to effective family planning methods
- In April 2022, ProMed unveiled the start of preclinical evaluations for resorbable contraceptive implants, a pioneering project backed by the Bill & Melinda Gates Foundation. This initiative focuses on developing cutting-edge contraceptive options that enhance patient safety and comfort, addressing the needs of diverse populations. With the foundation's significant support, ProMed aims to drive forward research and innovation in reproductive health, potentially transforming contraceptive choices for individuals worldwide
